Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model
Remi Mahmoud(University Medical Center Utrecht), Bas Oldenburg(University Medical Center Utrecht), Chris van Lieshout(University Medical Center Utrecht), Bindia Jharap(Meander Medisch Centrum), Geert Frederix(University Medical Center Utrecht)
Cited by 11
Related Papers
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
|Clinical and Translational Gastroenterology|2016|724
Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial
|The Lancet Oncology|2011|470
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252